US reform bites at Q1 financials
This article was originally published in Scrip
Executive Summary
As more companies reveal their first-quarter results and revise their financial guidance, the real effects of the US healthcare reform for the pharma industry are beginning to emerge. In many cases, prospects are being tempered to take account of the impact.